Literature DB >> 17126954

Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice.

Amy R Deipolyi1, Shanna Fang, Jorge J Palop, Gui-Qiu Yu, Xin Wang, Lennart Mucke.   

Abstract

Navigation deficits are prominent in Alzheimer's disease (AD) patients and transgenic mice expressing familial AD-mutant hAPP and A beta peptides. To determine the impact of strategy use on these deficits, we assessed hAPP and nontransgenic mice in a cross maze that can be solved by allocentric (world-based) or egocentric (self-based) strategies. Most nontransgenic mice used allocentric strategies, whereas half of hAPP mice were egocentric. At 3 months, all mice learned the cross maze rapidly; at 6 months, only allocentric hAPP mice were impaired. At 3 and 6 months, hAPP mice had reduced hippocampal Fos expression, which correlated with cross maze learning in older mice. Striatal pCREB expression was unaltered in hAPP mice, suggesting striatal sparing. We conclude that egocentric strategy use may be an earlier indicator of hAPP/A beta-induced hippocampal impairment than spatial learning deficits. Persistent use of allocentric strategies when egocentric strategies are available is maladaptive when there is hippocampal damage. Interventions promoting flexibility in selecting learning strategies might help circumvent otherwise debilitating navigational deficits caused by AD-related hippocampal dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17126954     DOI: 10.1016/j.neurobiolaging.2006.10.021

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  26 in total

Review 1.  Visual spatial cognition in neurodegenerative disease.

Authors:  Katherine L Possin
Journal:  Neurocase       Date:  2010-06-02       Impact factor: 0.881

2.  Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network.

Authors:  Julie A Harris; Nino Devidze; Laure Verret; Kaitlyn Ho; Brian Halabisky; Myo T Thwin; Daniel Kim; Patricia Hamto; Iris Lo; Gui-Qiu Yu; Jorge J Palop; Eliezer Masliah; Lennart Mucke
Journal:  Neuron       Date:  2010-11-04       Impact factor: 17.173

3.  Angiotensin IV Receptors Mediate the Cognitive and Cerebrovascular Benefits of Losartan in a Mouse Model of Alzheimer's Disease.

Authors:  Jessika Royea; Luqing Zhang; Xin-Kang Tong; Edith Hamel
Journal:  J Neurosci       Date:  2017-05-05       Impact factor: 6.167

4.  Mice Lacking GPR88 Show Motor Deficit, Improved Spatial Learning, and Low Anxiety Reversed by Delta Opioid Antagonist.

Authors:  Aura C Meirsman; Julie Le Merrer; Lucie P Pellissier; Jorge Diaz; Daniel Clesse; Brigitte L Kieffer; Jérôme A J Becker
Journal:  Biol Psychiatry       Date:  2015-06-06       Impact factor: 13.382

Review 5.  Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.

Authors:  Ji Won Um; Stephen M Strittmatter
Journal:  Prion       Date:  2012-09-17       Impact factor: 3.931

6.  Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.

Authors:  William J Meilandt; Moustapha Cisse; Kaitlyn Ho; Tiffany Wu; Luke A Esposito; Kimberly Scearce-Levie; Irene H Cheng; Gui-Qiu Yu; Lennart Mucke
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

Review 7.  Epilepsy and cognitive impairments in Alzheimer disease.

Authors:  Jorge J Palop; Lennart Mucke
Journal:  Arch Neurol       Date:  2009-02-09

8.  Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease.

Authors:  William J Meilandt; Gui-Qiu Yu; Jeannie Chin; Erik D Roberson; Jorge J Palop; Tiffany Wu; Kimberly Scearce-Levie; Lennart Mucke
Journal:  J Neurosci       Date:  2008-05-07       Impact factor: 6.167

9.  Impaired hippocampus-dependent and facilitated striatum-dependent behaviors in mice lacking the δ opioid receptor.

Authors:  Julie Le Merrer; Xavier Rezai; Grégory Scherrer; Jérôme A J Becker; Brigitte L Kieffer
Journal:  Neuropsychopharmacology       Date:  2013-01-04       Impact factor: 7.853

10.  Losartan improves cerebrovascular function in a mouse model of Alzheimer's disease with combined overproduction of amyloid-β and transforming growth factor-β1.

Authors:  Panayiota Papadopoulos; Xin-Kang Tong; Hans Imboden; Edith Hamel
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.